zantac 75 tablete
filmsko obložena tableta - ranitidin
atacand plus 16 mg/12,5 mg tablete
astrazeneca ab - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 12,5 mg / 1 tableta cileksetilkandesartanat16 mg / 1 tableta; cileksetilkandesartanat 16 mg / 1 tableta - kandesartan in diuretiki
atacand 16 mg tablete
astrazeneca ab - cileksetilkandesartanat - tableta - cileksetilkandesartanat 16 mg / 1 tableta - kandesartan
atacand 8 mg tablete
astrazeneca ab - cileksetilkandesartanat - tableta - cileksetilkandesartanat 8 mg / 1 tableta - kandesartan
atacand 4 mg tablete
astrazeneca ab - cileksetilkandesartanat - tableta - cileksetilkandesartanat 4 mg / 1 tableta - kandesartan
atacand plus 32 mg/12,5 mg tablete
astrazeneca uk limited - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 12,5 mg / 1 tableta cileksetilkandesartanat32 mg / 1 tableta; cileksetilkandesartanat 32 mg / 1 tableta - kandesartan in diuretiki
atacand 32 mg tablete
astrazeneca uk limited - cileksetilkandesartanat - tableta - cileksetilkandesartanat 32 mg / 1 tableta - kandesartan
atacand plus 32 mg/25 mg tablete
astrazeneca uk limited - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 25 mg / 1 tableta cileksetilkandesartanat32 mg / 1 tableta; cileksetilkandesartanat 32 mg / 1 tableta - kandesartan in diuretiki
quantalan peroralni prašek
kemofarmacija d.d. - peroralni prašek - holestiramin
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.